Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New canine oral cancer drug to be trialled
Owners of dogs with oral melanoma are being encouraged to participate in the trial.
The drug is already licensed to another form of canine cancer.

A pilot trial is set to be carried out to test the ability of a drug derived from berries to treat canine oral melanoma.

Researchers at the Royal (Dick) School of Veterinary Studies in Edinburgh, Scotland will assess the effectiveness of the drug tigilanol tiglate, which is derived from the berries of the blushwood tree, a species found in Queensland, Australia.

The drug, which disrupts blood vessels inside tumours without harming healthy tissue, is currently licensed to treat mast cell tumours. If it is shown to work to treat canine oral melanoma, it may save some dogs from having to undergo surgery.

The researchers hope that the trial could also provide insights that could benefit human medicine, as canine oral melanoma shares many features with human mucosal melanoma. In both diseases, symptoms typically remain hidden until the disease has already reached an advanced stage.

The research is being funded by QBiotics, the manufacturer of tigilanol tiglate, which it sells under the brand name Stelfonta.

The trial will involve eight dogs, although the number of participating animals may be increased if the initial results prove to be promising. Owners of eligible dogs are being asked to get in touch with the research team.

Kelly Blacklock, professor of small animal soft tissue surgery, said: “If successful, this treatment could transform the way we approach cancer therapy in veterinary medicine, sparing many dogs from the need for surgery.

“We encourage pet owners with dogs diagnosed with oral melanoma to consider participating in this trial. Your involvement could not only contribute to advancing treatment options for this challenging disease but also help improve the quality of life for dogs in the future.”

Eligible dog owners wishing to take part should email Professor Blacklock.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Free CPD announced for BVNA members

News Story 1
 Zoetis is to present a CPD event for free to members of the British Veterinary Nursing Association (BVNA).

Led by veterinary consultant Ruth Moxon, the one-hour online session is designed to help veterinary nurses discuss parasiticide options with clients. It will advise on structuring recommendations, factors for product choice and moving away from 'selling'.

'How do you recommend parasite treatments to your clients?' will be presented on Tuesday, 20 May at 7.30pm. It is free for BVNA members, with £15.00 tickets for non-members.

Veterinary nurses can email cpd@bvna.co.uk to book their place. 

Click here for more...
News Shorts
DAERA to reduce BVD 'grace period'

DAERA has reminded herd keepers of an upcoming reduction to the 'grace period' to avoid BVD herd restrictions.

From 1 May 2025, herd keepers will have seven days to cull any BVD positive or inconclusive animals to avoid restrictions being applied to their herd.

It follows legislation introduced on 1 February, as DAERA introduces herd movement restrictions through a phased approach. Herd keepers originally had 28 days to cull BVD positive or inconclusive animals.

DAERA says that, providing herd keepers use the seven-day grace period, no herds should be restricted within the first year of these measures.

Additional measures, which will target herds with animals over 30 days old that haven't been tested for BVD, will be introduced from 1 June 2025.

More information is available on the DAERA website.